225Ac-PSMA RLT is an efficacious and safe treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). Future randomized controlled trials are required to establish its therapeutic efficacy and survival benefit vis-à-vis other approved treatment modalities.